Treatment with pembrolizumab in a patient with non-small cell lung cancer after a faecal transplantation - case report
Abstract
The advent of immunotherapy in the treatment of non-small cell lung cancer has prolonged the lives of a large proportion of patients. If the patient's body responds to treatment and manages to activate anti-tumor immunity, it is considered a success.
However, in practice, we often encounter situations where, despite our best efforts, things do not go as planned and the patient does not benefit from the treatment. Many questions remain as to why this is the case.
One theory suggests that the composition of the gut microbiome may determine why certain groups of patients benefit while others do not. Our case report shows a significant treatment response in a patient with adenocarcinoma who underwent fecal transplantation.
A year after diagnosis, we are becoming optimistic.